Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer

ABSTRACT: Clear-cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, which is often resistant to conventional cancer therapies including chemotherapy and radiation therapy. Targeted treatments including immunotherapies and small molecule inhibitors have been recently developed with positive outcomes. However, variations in the patient response and resistance to therapies suggest that models that better recapitulate the pathogenesis and metastatic mechanisms of ccRCC are required to improve our understanding and subsequent management of ccRCC. Here, we examined the transcriptional landscapes of in vitro as well as orthotopic and metastatic NOD/SCID-γ mouse models of ccRCC using the RCC243 cell line established from the primary tumour of a patient that was diagnosed with metastatic ccRCC. Notably, RCC243 cells developed metastatic tumours using assays in mouse models, and they retained their clear-cell morphology irrespective of model type but exhibited differential gene expression profiles between models of RCC243, highlighting the impact of the cellular environment and the stage of disease progression. Furthermore, we identified prognostic markers that were conserved between RCC243 models and patient ccRCC tumour datasets and showed that genes that were upregulated in the metastatic RCC243 model were associated with worse prognosis in patients. Overall, this study presents a novel metastatic model of ccRCC, highlights the role of the cellular environment on the transcriptome, and demonstrates the importance of the choice of an experimental model.

ORGANISM(S): Homo sapiens

PROVIDER: GSE272610 | GEO | 2025/04/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from different samples of a single ccRCC patient: 7 primary intra-tumor samples and 2 metastatic tumor samples

2011-08-25 | GSE31610 | GEO

Expression data from different samples of a single ccRCC patient: 8 primary intra-tumor samples and 2 metastatic tumor samples

Project description:We have sampled several tumour regions from a single ccRCC patient after 6 weeks everolimus treatment, including both primary and metastatic site samples to investigate intra-tumour heterogeneity. We selected 8 samples from the primary tumour, and 2 samples from a chestwall metastatic site for expression analysis using microarray data. All samples were fresh frozen upon extraction.

2011-08-24 | E-GEOD-31610 | biostudies-arrayexpress

Gene array analysis of clear cell renal cell carcinoma tissue versus matched normal kidney tissue

Project description:Currently there is a lack of effective therapies which result in long-term durable response for patients presenting with advanced and metastatic clear cell renal cell carcinoma (ccRCC). This is due in part to a lack of molecular factors which can be targeted pharmacologically. In order to identify novel tumor-specific targets, we performed high throughput gene array analysis screening numerous patient ccRCC tumor tissues across all stages of disease, and compared their gene expression levels to matched normal kidney. Our results identify a number of genes which demonstrate tumor-specific overexpression, and may present as novel targets for therapy. Patient tissue samples were sorted into disease stages based on pathology reports. RNA was extracted from flash frozen patient tumor and normal samples. Gene array analysis was performed, and resulting expression levels were compared between normal and tumor samples.

2014-01-03 | E-GEOD-53757 | biostudies-arrayexpress

Molecular Profiling Reveals Immunosuppressive Tumor Immune Microenvironment in Primary versus Paired Asynchronous Metastatic Clear Cell Renal Cell Carcinoma

Project description:Clear cell renal cell carcinoma (ccRCC) is a highly immune infiltrated cancer, but how the tumor immune microenvironment (TIME) evolves during disease progression is unknown. Insights into heterogeneity within primary ccRCC raise questions about potential heterogeneity between primary and paired metastatic tumors. This information may improve understanding of immune evasion leading to metastatic disease and response to immunotherapy. In this study, we characterize and compare the TIME of primary ccRCC with paired asynchronous metastases. We demonstrate higher infiltration of immunosuppressive cells in the TIME of primary ccRCC compared with metastatic sites. Further studies are necessary to determine the prognostic and therapeutic significance of these findings. Understanding the heterogeneity of the tumor immune microenvironment in RCC, both intratumorally and between metastatic sites, has important clinical implications for selecting appropriate therapies and developing predictive biomarkers. Future research should focus on elucidating the impact of these findings on immunotherapeutic responses and patient outcomes in ccRCC.

2024-09-27 | GSE278174 | GEO

Gene expression analysis of ccRCC cell line upon SETD2 rescue [RNAseq_JHRCC12]

Project description:SETD2, a H3K36 trimethyltransferase, is frequently mutated in human cancers with the highest prevalence (13%) in clear cell renal cell carcinoma (ccRCC). Genomic profiling of primary ccRCC tumors reveals a positive correlation between SETD2 mutations and metastasis. However, whether and how SETD2-loss promotes metastasis remains unclear. Here, we detected SETD2 mutations in 24 of 51 (47%) metastatic ccRCC tumors. Using SETD2-mutant metastatic ccRCC patient-derived cell line and xenograft models, we showed that H3K36me3 restoration greatly reduced distant metastases of ccRCC in mice. An integrated ATAC-seq, ChIP-seq, and transcriptome analysis concluded a tumor suppressor model in which loss of SETD2-mediated H3K36me3 activates enhancers to drive oncogenic transcription through dysregulating histone chaperone recruitment, enhancing histone exchange, and expanding chromatin accessibility. Furthermore, we uncovered mechanism-based therapeutic strategies for SETD2-deficient cancer through inhibition of histone chaperones. Overall, SETD2-loss creates a permissive epigenetic landscape for cooperating oncogenic drivers to amplify transcriptional output, providing unique therapeutic opportunities.

2021-11-15 | GSE146540 | GEO

Chromatin landscape analysis of murine renal tubular epithelial cells upon SETD2 knockout [ATACseq_RTE]

2021-11-15 | GSE146538 | GEO

Chromatin landscape analysis of ccRCC cell line upon SETD2 rescue [ATACseq_JHRCC12]

2021-11-15 | GSE146537 | GEO

Gene expression analysis of murine renal tubular epithelial cells upon SETD2 knockout [RNAseq_RTE]

2021-11-15 | GSE146541 | GEO

Genome binding/occupancy profiling of ccRCC cell line upon SETD2 rescue [ChIPseq_JHRCC12]

2021-11-15 | GSE146539 | GEO

Immunosuppressive crosstalk between tumour, myeloid and T cells in an anti-PD-1 plus anti-CTLA-4 therapy resistant mouse ccRCC model [scRNA-seq]

Project description:Many patients respond poorly or develop resistance to immune checkpoint therapies for metastatic clear cell renal cell carcinoma (ccRCC). Here we demonstrate that ccRCCs in the Vhl/Trp53/Rb1 mutant autochthonous mouse model are resistant to anti-PD-1 plus anti-CTLA-4 therapy, providing a model of checkpoint therapy resistance. In vivo checkpoint therapy allowed isolated T cells to recognise cultured ccRCC cells, implicating the tumour microenvironment in suppression of T cell activation. Single cell RNA-seq identified putative immunosuppressive PMN-MDSC, M-MDSC and TAM populations that show similar features to myeloid cells in the microenvironment of human ccRCC. Conditioned medium of ccRCC cell lines attracted bone marrow-derived macrophages in a MIF-dependent manner and induced the mis-differentiation of bone marrow cells to M-MDSC and TAM2-like phenotypes. These cells suppressed the viability and proliferation of activated CD8+ T cells. These analyses identify new candidate cellular and molecular barriers to effective immune checkpoint therapy. We validate this concept by showing that GALECTIN-3 is the predominant checkpoint ligand expressed by ccRCC cells and myeloid cells and that anti-LAG-3 treatment increases T cell infiltration in this model.

2025-02-27 | GSE259361 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data